MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
0.3020
+0.0119
+4.10%
After Hours: 0.3135 +0.0115 +3.81% 19:45 05/12 EDT
OPEN
0.2986
PREV CLOSE
0.2901
HIGH
0.3065
LOW
0.2862
VOLUME
352.66K
TURNOVER
--
52 WEEK HIGH
3.426
52 WEEK LOW
0.2425
MARKET CAP
21.48M
P/E (TTM)
-0.8101
1D
5D
1M
3M
1Y
5Y
1D
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
NASDAQ · 1d ago
Weekly Report: what happened at OVID last week (0505-0509)?
Weekly Report · 1d ago
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at OVID last week (0428-0502)?
Weekly Report · 05/05 09:18
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/01 11:40
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
NASDAQ · 04/29 12:15
Weekly Report: what happened at OVID last week (0421-0425)?
Weekly Report · 04/28 09:20
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 04/24 21:05
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.